A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Terminated
Merck Sharp & Dohme Corp.
Phase 1
2009-02-05
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for
the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0
months to 17 years of age.
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
Terminated
National Cancer Institute (NCI)
Phase 2
2009-02-01
RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help
lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck
cancer undergoing chemotherapy and radiation therapy.
PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with
palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused
by cisplatin in patients with stage III or stage IV head and neck cancer undergoing
chemotherapy and radiation therapy.
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
Terminated
University of Washington
Phase 2
2009-02-01
RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help
lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck
cancer undergoing chemotherapy and radiation therapy.
PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with
palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused
by cisplatin in patients with stage III or stage IV head and neck cancer undergoing
chemotherapy and radiation therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
